Adverse Reactions to BiologicsAvailable to Purchase
In many areas of medicine physicians still face the great challenge of finding therapies that will meet the patients’ needs. In dermatology the challenge has arisen on multiple fronts through advances in the understanding of the immunopathogenesis of many inflammatory and malignant cutaneous disorders. Breakthroughs, combined with significant developments in targeted immunotherapy, have resulted in improved outcomes as these newer therapies are being used for both approved indications and as off-label therapies for various chronic inflammatory skin disorders and many forms of skin cancer.
In the expectation that by truly understanding the safety profile of these targeted therapies patients’ outcomes will be significantly improved, this book offers insights into topics such as adverse reactions, infectious complications and the perioperative use of biologics in psoriasis, immunogenicity of biologic therapies, paradoxical reactions, safety of biologics used to treat autoimmune bullous diseases and primary cutaneous lymphomas, adverse reactions and skin manifestations of therapies targeting melanoma and non-melanoma skin cancer and other neoplastic diseases.
Eminent researchers with extensive clinical experience have contributed to this publication, providing an in-depth overview of the latest knowledge in this field.
Download citation file:
Digital Version
Print Version
Table of Contents
-
1 - 14: Adverse Reactions to Biologics in PsoriasisByStephen J. Lockwood;Stephen J. LockwoodaDepartment of Dermatology, Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, Harvard Medical School,Search for other works by this author on:Lisette M. Prens;Lisette M. PrensaDepartment of Dermatology, Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, Harvard Medical School,Search for other works by this author on:Alexa B. KimballAlexa B. KimballbHarvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, andcHarvard Medical School, Boston, MA, USASearch for other works by this author on:
-
15 - 27: Clinical Trial and Registry DataByMelinda Gooderham;Melinda GooderhamaSkin Centre for Dermatology, Peterborough, ON,bProbity Medical Research, Waterloo, ON,cQueen's University, Kingston, ON, andSearch for other works by this author on:Kim PappKim PappbProbity Medical Research, Waterloo, ON,dK. Papp Clinical Research, Waterloo, ON, CanadaSearch for other works by this author on:
-
28 - 36: Immunosuppression/Infections across IndicationsByAyida Al-Khalili;Ayida Al-KhaliliDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, CanadaSearch for other works by this author on:Jan P. DutzJan P. DutzDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, CanadaSearch for other works by this author on:
-
37 - 48: The Immunogenicity of Biologic TherapiesBySandra Garcês;Sandra GarcêsaEli Lilly and Company, Indianapolis, IN, USA;Search for other works by this author on:Jocelyne DemengeotJocelyne DemengeotbInstituto Gulbenkian de Ciencia, Oeiras, PortugalSearch for other works by this author on:
-
49 - 63: Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and OthersByLluís PuigLluís PuigDepartment of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, SpainSearch for other works by this author on:
-
64 - 69: Bullous DiseasesByCaroline Corbaux;Caroline CorbauxDepartment of Dermatology, Rouen University Hospital and INSERM U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, Normandie University, Rouen, FranceSearch for other works by this author on:Pascal JolyPascal JolyDepartment of Dermatology, Rouen University Hospital and INSERM U1234, Centre de Référence des Maladies Bulleuses Autoimmunes, Normandie University, Rouen, FranceSearch for other works by this author on:
-
70 - 81: Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and MogamulizumabByI. Saulite;I. SauliteaDepartment of Dermatology/Allergology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland;bDepartment of Infectology and Dermatology, Riga Stradins University, Riga, Latvia;Search for other works by this author on:E. Guenova;E. GuenovaaDepartment of Dermatology/Allergology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland;cDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland;Search for other works by this author on:W. HoetzeneckerW. HoetzeneckeraDepartment of Dermatology/Allergology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland;dDepartment of Dermatology, Kepler University Hospital, Linz, AustriaSearch for other works by this author on:
-
82 - 92: Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab)ByShelley Ji Eun Hwang;Shelley Ji Eun HwangaDepartment of Dermatology, Westmead Hospital, Sydney, andbSydney Medical School, The University of Sydney, Sydney, AustraliaSearch for other works by this author on:Pablo Fernández-PeñasPablo Fernández-PeñasaDepartment of Dermatology, Westmead Hospital, Sydney, andbSydney Medical School, The University of Sydney, Sydney, AustraliaSearch for other works by this author on:
-
93 - 104: Skin Manifestations of Targeted Antineoplastic TherapyByOnofre SanmartínOnofre SanmartínDepartment of Dermatology, Instituto Valenciano de Oncologia, Valencia, SpainSearch for other works by this author on:
